|
|
|
|
Callisto Pharmaceuticals to Present at Rodman & Renshaw
Techvest Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Oct. 21, 2003--Callisto Pharmaceuticals,
Inc. (OTCBB: CLSP - News) announced today that it will participate
in the Rodman & Renshaw Techvest Healthcare Conference, to be held October
21 - 23, 2003 at the Boston Marriott Long Wharf Hotel in Boston,
MA. Gary S. Jacob, Ph.D., CEO of Callisto, is scheduled to speak
at 6:00 PM EDT on
October 22, 2003 and is expected to discuss Callisto's drug development
programs directed towards multiple myeloma, osteolytic bone disease
and other cancers.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company primarily focused on
the development of drugs to treat multiple myeloma, osteolytic
bone disease and other cancers. Callisto's lead drug candidate, Atiprimod,
is
a small-molecule,
orally available drug with antiproliferative and antiangiogenic
activity. Atiprimod successfully completed Phase I clinical trials
in rheumatoid arthritis
patients and Callisto filed an IND on September 23, 2003 with
the U.S. Food and Drug Administration on Atiprimod to enter
a Phase
I/IIa clinical
trial
in multiple myeloma patients. The drug is also being explored
as an agent to treat osteolytic bone disease. In addition,
Callisto has programs
focused
on the development of an analog of the human intestinal hormone,
uroguanylin, to treat colon cancer, and drugs to protect against
staphylococcal and streptococcal
bioweapons, as a protection against the devastating effects of
toxic shock syndrome. Callisto has two operating subsidiaries,
Callisto Research Labs,
LLC and Synergy Pharmaceuticals Inc.
Included in this release are "forward-looking: statements. Such statements
are indicated by words such as "expect," "should," "anticipate" and
similar words indicating uncertainty in facts and figures. Although
Callisto believes that the expectations reflected in such forward-looking
statements
are reasonable, it can give no assurance that such expectations
reflected in such forward-looking statements will prove to have been correct.
Callisto's
actual results could differ materially from those anticipated in
the forward-looking statements as a result of various factors.
|
|
|
|
|